Beyond The Numbers: 21 Analysts Discuss Biogen Stock
During the last three months, 21 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 14 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 4 | 2 | 8 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 2 | 1 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $197.43, a high estimate of $246.00, and a low estimate of $143.00. Surpassing the previous average price target of $174.60, the current average has increased by 13.08%.
Diving into Analyst Ratings: An In-Depth Exploration
In examining recent analyst actions, we gain insights into how financial experts perceive Biogen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Emily Field | Barclays | Announces | Equal-Weight | $185.00 | - |
| Laura Chico | Wedbush | Raises | Neutral | $187.00 | $178.00 |
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $230.00 | $220.00 |
| Evan Seigerman | BMO Capital | Raises | Market Perform | $196.00 | $165.00 |
| David Amsellem | Piper Sandler | Raises | Neutral | $177.00 | $157.00 |
| Phil Nadeau | TD Cowen | Raises | Buy | $215.00 | $175.00 |
| Geoff Meacham | Citigroup | Raises | Neutral | $215.00 | $185.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $233.00 | $217.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $246.00 | $185.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $200.00 | $190.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Hold | $193.00 | $190.00 |
| Laura Chico | Wedbush | Raises | Neutral | $187.00 | $178.00 |
| Andrew S. Fein | HC Wainwright & Co. | Raises | Buy | $228.00 | $194.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $225.00 | $205.00 |
| Geoff Meacham | Citigroup | Raises | Neutral | $185.00 | $180.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Hold | $190.00 | $142.00 |
| Geoff Meacham | Citigroup | Raises | Neutral | $180.00 | $153.00 |
| Michael Yee | UBS | Raises | Neutral | $185.00 | $130.00 |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $156.00 | $149.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $190.00 | $155.00 |
| Rajesh Kumar | HSBC | Lowers | Reduce | $143.00 | $144.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biogen compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Biogen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Biogen analyst ratings.
Unveiling the Story Behind Biogen
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biogen's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Biogen's revenue growth over a period of 3M has faced challenges. As of 31 December, 2025, the company experienced a revenue decline of approximately -7.14%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -2.15%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Biogen's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.27%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Biogen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.17%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.